Key disease parameters in all patients who continued in the 18-month extension phase
| Parameter . | No. evaluable patients . | No. patients (%) . | ||
|---|---|---|---|---|
| Stable . | Improved . | Worsened . | ||
| Liver volume | 27 | 26 (96) | 1 (3) | 0 (0) |
| Spleen volume* | 20 | 20 (71) | 0 (0) | 0 (0) |
| Hemoglobin | 28 | 25 (89) | 2 (3) | 1 (3) |
| Platelets | 28 | 25 (89) | 2 (3) | 1 (3) |
| Chitotriosidase | 28 | 27 (96) | 0 (0) | 1 (3) |
| Parameter . | No. evaluable patients . | No. patients (%) . | ||
|---|---|---|---|---|
| Stable . | Improved . | Worsened . | ||
| Liver volume | 27 | 26 (96) | 1 (3) | 0 (0) |
| Spleen volume* | 20 | 20 (71) | 0 (0) | 0 (0) |
| Hemoglobin | 28 | 25 (89) | 2 (3) | 1 (3) |
| Platelets | 28 | 25 (89) | 2 (3) | 1 (3) |
| Chitotriosidase | 28 | 27 (96) | 0 (0) | 1 (3) |
Key disease parameters based on calculation for remaining disease, as described in “Statistical analysis.”
Seven patients were splenectomized before entry into the study.